UCB withdraws EU application for expanded use of Vimpat

09/26/2008 | Reuters

The European Medicines Agency's negative review of Vimpat's use in diabetic neuropathic pain has prompted UCB SA to drop its EU application for the expanded use of the epilepsy treatment. A UCB spokeswoman said the Belgian drugmaker plans to conduct an additional clinical study "to further substantiate the magnitude" of Vimpat's effects in patients with diabetic neuropathic pain.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ